발기부전 환자에서 Phosphodiesterase5 억제제의 재처방률과 효과에도 불구하고 복용을 중단하게 된 이유 = The Refill Rate and Reasons for Abandonment of Phosphodiesterase5 Inhibitors in Erectile Dysfunction Patients

참고문헌 (Reference)

1 박남철, "항고혈압제를 복용 중인 발기부전 환자에서 실데나필의 안전성과 유효성을 평가하기 위한 다기관, 공개, 용량조절 임상시험" 대한비뇨기과학회 46 (46): 1015-1022, 2005

2 손환철, "실데나필 투약으로 발기능 회복 이후의 투약 중단 원인" 대한남성과학회 22 (22): 11-13, 2004

3 김민수, "다종의 경구용 발기부전치료제 시대를 맞아 대학병원을 찾는 발기부전환자의 발기부전치료에 대한 인식도" 대한남성과학회 24 (24): 18-22, 2006

4 Braun M, "‘Viagra effect' - influence of mass media on patient behavior" 66 : 145-148, 2001

5 Klotz T, "Why do patients with erectile dysfunction abandon effective therapy with sildenafil(Viagra)?" 17 : 2-4, 2005

6 Ayta IA, "The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences" 84 : 50-56, 1999

7 Rosen RC, "The Multinational Men's Attitudes to Life Events and Sexuality(MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population" 20 : 607-617, 2004

8 Terradas C, "Sildenafil improves nocturnal penile erections in organic impotence" 13 : 125-129, 2001

9 Laumann EO, "Sexual dysfunction in the United States: prevalence and predictors" 281 : 537-544, 1999

10 Kim NN, "Phosphodiesterase type 5 inhibitors: a biochemical and clinical correlation survey" 15 (15): S13-S19, 2003

11 Rosen RC, "Overview of phosphodiesterase 5 inhibition in erectile dysfunction" 92 : 9M-18M, 2003

12 Christiansen E, "Long-term efficacy and safety of oral Viagra(sildenafil citrate) in men with erectile dysfunction and the effect of randomised treatment withdrawal" 12 : 177-182, 2000

13 Sommer F, "Improved spontaneous erectile function in men with mild-to-moderate arteriogenic erectile dysfunction treated with a nightly dose of sildenafil for one year: a randomized trial" 9 : 134-141, 2007

14 NIH Consensus Conference, "Impotence. NIH Consensus Development Panel on Impotence" 270 : 83-90, 1993

15 Feldman HA, "Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study" 151 : 54-61, 1994

16 Braun M, "Epidemiology of erectile dysfunction: results of the ‘Cologne Male Survey'" 12 : 305-311, 2000

17 Rochira V, "Effects of sildenafil on nocturnal penile tumescence and rigidity in normal men: randomized, placebo-controlled, crossover study" 23 : 566-571, 2002

18 van Lankveld JJ, "Cognitive changes predict continued recovery of erectile functioning versus relapse after discontinuation of sildenafil treatment for male erectile dysfunction" 65 : 709-718, 2003

19 Lee U, "Clinical efficacy and safety of sildenafil in the men with erectile dysfunction in Korea" 42 : 435-440, 2001

20 Rosano GM, "Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk" 47 : 214-220, 2005

21 Saenz dTI, "Anatomy, physiology and pathophysiology of erectile dysfunction" Health Publications 65-102, 2000

22 Desouza C, "Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type 2 diabetes" 25 : 1336-1339, 2002